论文部分内容阅读
目的探讨分化抑制因子3(ID3)、VEGF和CD34在胃癌组织中的表达及临床意义。方法采用免疫组化检测80例胃癌组织(胃癌组)和80例切缘癌旁组织(癌旁组)中ID3、VEGF以及CD34的表达,并分析其相关性。结果胃癌组ID3、VEGF和CD34的阳性表达率分别为78.75%、63.75%和62.50%,高于癌旁组的28.75%、22.50%和26.25%(P<0.05)。胃癌组织中ID3与VEGF、CD34的表达相关(P<0.05)。结论 ID3、VEGF和CD34与胃癌的发生、发展密切相关,联合检测可用于判断胃癌患者的预后。
Objective To investigate the expression and clinical significance of differentiation inhibitor 3 (ID3), VEGF and CD34 in gastric cancer. Methods The expressions of ID3, VEGF and CD34 were detected by immunohistochemistry in 80 cases of gastric cancer (gastric cancer group) and 80 cases of paracancerous tissues (paracancer group), and the correlation was analyzed. Results The positive rates of ID3, VEGF and CD34 in gastric cancer group were 78.75%, 63.75% and 62.50%, respectively, which were higher than those in adjacent non-cancer group (28.75%, 22.50% and 26.25%, P <0.05). The expression of ID3 and VEGF, CD34 in gastric cancer tissues was correlated (P <0.05). Conclusion ID3, VEGF and CD34 are closely related to the occurrence and development of gastric cancer. Combined detection can be used to judge the prognosis of patients with gastric cancer.